UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________

 

FORM 8-K

___________________

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): May 26, 2020

 

CELLECTAR BIOSCIENCES, INC.

(Exact name of registrant as specified in charter)

 

Delaware   1-36598   04-3321804

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

100 Campus Drive, Florham Park, New Jersey 07932
(Address of principal executive offices, and zip code)

 

(608) 441-8120
(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered

Common stock, par value $0.00001

Warrant to purchase common stock, expiring April 20, 2021 

 

CLRB

CLRBZ

 

NASDAQ Capital Market 

NASDAQ Capital Market

 

 

     

 

 

ITEM 7.01 REGULATION FD DISCLOSURE

 

On May 26, 2020, we issued a press release announcing that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) in patients having received two prior treatment regimens or more. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.

 

ITEM 8.01 OTHER EVENTS

 

The information set forth under “Item 7.01. Regulation FD Disclosure” is incorporated into this Item 8.01 by reference.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits

 

Number   Title
99.1   Press release dated May 26, 2020, titled “Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia”

 

  2  

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: May 26, 2020 CELLECTAR BIOSCIENCES, INC.  
             
             
  By:   /s/ Dov Elefant  
      Name:   Dov Elefant  
    Title:   Chief Financial Officer  

 

 

  3  

Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Jul 2020 to Aug 2020 Click Here for more Cellectar Biosciences Charts.
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Aug 2019 to Aug 2020 Click Here for more Cellectar Biosciences Charts.